Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with hepatocellular carcinoma (HCC) has been dosed...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Life...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Life Science Day,...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid...
Read morePositive MIV-818 data presented at ESMO. New positive data and renegotiated agreement for remetinostat July – September Financial summary for the...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled “Phase 1 study of the novel prodrug...
Read more